First-In-Human Phase 1 Trial of IO-108, an Antagonist Antibody Targeting LILRB2 (ILT4), as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors: Dose Escalation Data (NCT05054348)
Document Type
Presentation
Publication Date
4-18-2023
Keywords
oregon; chiles
Abstract
AACR Annual Meeting; 2023 April 18; Orlando, FL
Clinical Institute
Cancer
Department
Oncology
Recommended Citation
Taylor, M, "First-In-Human Phase 1 Trial of IO-108, an Antagonist Antibody Targeting LILRB2 (ILT4), as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors: Dose Escalation Data (NCT05054348)" (2023). Articles, Abstracts, and Reports. 7978.
https://digitalcommons.providence.org/publications/7978
